



August 21, 2025

Dept. of Corporate Services  
**BSE Ltd.**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001.

Listing Department  
**National Stock Exchange of India Ltd.**  
Exchange Plaza,  
Bandra Kurla Complex  
Bandra (East), Mumbai 400051.

**BSE Scrip Code: 524735**

**NSE Symbol: HIKAL**

**Subject: Hikal's Jigani Unit- US FDA Inspection - Updates.**

Ref: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 8<sup>th</sup> February 2025 & 23<sup>rd</sup> May, 2025 regarding the United States Food and Drug Administration (US FDA) inspection of one of our manufacturing facilities at Jigani, Bengaluru, Karnataka from February 3<sup>rd</sup> to February 7<sup>th</sup>, 2025. We hereby notify that the Company has received a warning letter from the US FDA for the Company's Jigani, Bengaluru facility on Aug 20<sup>th</sup>, 2025.

The Company remains committed to work closely with the US FDA to resolve the issues at the earliest. We uphold quality and compliance issues with utmost importance and remain committed to be compliant with cGMP quality standards across all our manufacturing facilities.

We request you to take the above on record.

Thanking you,

Yours Sincerely,  
**for HIKAL LIMITED,**

**Rajasekhar Reddy**  
**Company Secretary and Compliance Officer**

**Hikal Ltd.**

**Admin. Office:** Great Eastern Chambers, 6<sup>th</sup> Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

**Regd. Office:** 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com    info@hikal.com    CIN: L24200MH1988PTC048028